RJFSA
EVOK

Raymond James Financial Services Advisors’s Evoke Pharma EVOK Stock Holding History

Raymond James Financial Services Advisors’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-754
Closed -$54K – 3308
2022
Q1 		$54K Hold
754
– – ﹤0.01% 3187
2021
Q4 		$60K Hold
754
– – ﹤0.01% 3167
2021
Q3 		$141K Sell
754
-74
-9% -$12.5K ﹤0.01% 3066
2021
Q2 		$163K Buy
+828
New +$177K ﹤0.01% 3060

Other funds holding EVOK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Raymond James Financial Services Advisors's EVOK Position: Q2 2022 in Review

Raymond James Financial Services Advisors sold out of Evoke Pharma (EVOK) in Q2 2022, closing a stake of 754 shares — an estimated $54K sold.

Raymond James Financial Services Advisors first reported a position in EVOK in Q2 2021 and held it in 4 quarters. The position peaked at $163K in Q2 2021. 12 funds tracked by Wall St. Rank hold EVOK as of Q2 2022.

  • Raymond James Financial Services Advisors reported no remaining Evoke Pharma position as of Q2 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 754 Evoke Pharma shares in Q2 2022, an estimated $54K.
  • Raymond James Financial Services Advisors first reported a position in Evoke Pharma in Q2 2021 and held it in 4 quarters.
  • Raymond James Financial Services Advisors's Evoke Pharma position peaked at $163K in Q2 2021.
  • 12 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.